Wegovy is a GLP-1 receptor agonist anti-obesity medication that has several cardiovascular benefits, based on data from the SELECT Trial published last fall in The New England Journal of Medicine
That sub-criterion scored 0 and is the reason this category lands at 75 instead of 100
Low levels of glutathione have been connected to an increased risk of diseases such as arthritis, diabetes, cardiovascular diseases and cancer
International Diabetes Federation IDF Diabetes Atlas
More practically, the drugs suppress appetite, slow digestion, and boost satiety, which can lead to quick weight loss because people on them, well, just dont feel the urge to eat
Does Kentucky Medicaid cover GLP-1 for weight loss